9,972 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Acquired by Hanseatic Management Services Inc.

Hanseatic Management Services Inc. purchased a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 9,972 shares of the biopharmaceutical company’s stock, valued at approximately $610,000. Intra-Cellular Therapies makes up 1.0% of Hanseatic Management Services Inc.’s investment portfolio, making the stock its 29th biggest position.

Other large investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its stake in Intra-Cellular Therapies by 11.7% during the first quarter. JPMorgan Chase & Co. now owns 157,144 shares of the biopharmaceutical company’s stock worth $9,615,000 after buying an additional 16,454 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Intra-Cellular Therapies by 5.2% during the first quarter. Bank of New York Mellon Corp now owns 385,508 shares of the biopharmaceutical company’s stock worth $23,591,000 after buying an additional 18,999 shares during the last quarter. Cambridge Investment Research Advisors Inc. acquired a new position in Intra-Cellular Therapies during the first quarter worth $349,000. PNC Financial Services Group Inc. boosted its stake in Intra-Cellular Therapies by 25.6% during the first quarter. PNC Financial Services Group Inc. now owns 5,909 shares of the biopharmaceutical company’s stock worth $363,000 after buying an additional 1,204 shares during the last quarter. Finally, Natixis Advisors L.P. boosted its stake in Intra-Cellular Therapies by 71.3% during the first quarter. Natixis Advisors L.P. now owns 18,165 shares of the biopharmaceutical company’s stock worth $1,112,000 after buying an additional 7,558 shares during the last quarter. 86.94% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Intra-Cellular Therapies news, CFO Lawrence J. Hineline sold 81,854 shares of the company’s stock in a transaction dated Wednesday, June 14th. The stock was sold at an average price of $63.97, for a total transaction of $5,236,200.38. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, EVP Mark Neumann sold 55,300 shares of the stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $58.79, for a total value of $3,251,087.00. Following the transaction, the executive vice president now owns 45,339 shares in the company, valued at approximately $2,665,479.81. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Lawrence J. Hineline sold 81,854 shares of the stock in a transaction dated Wednesday, June 14th. The shares were sold at an average price of $63.97, for a total value of $5,236,200.38. The disclosure for this sale can be found here. Insiders have sold a total of 138,996 shares of company stock worth $8,607,017 in the last quarter. 3.40% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $73.00 price target on shares of Intra-Cellular Therapies in a research note on Thursday, August 3rd. JPMorgan Chase & Co. upped their price target on Intra-Cellular Therapies from $58.00 to $62.00 in a research note on Monday, June 5th. StockNews.com assumed coverage on Intra-Cellular Therapies in a research note on Wednesday, August 23rd. They issued a “hold” rating on the stock. Morgan Stanley reaffirmed an “overweight” rating and issued a $80.00 price target on shares of Intra-Cellular Therapies in a research note on Friday, August 4th. Finally, Royal Bank of Canada upped their price target on Intra-Cellular Therapies from $78.00 to $79.00 and gave the company an “outperform” rating in a research note on Friday, August 4th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $78.78.

Intra-Cellular Therapies Price Performance

ITCI opened at $58.70 on Friday. The stock’s 50-day moving average price is $59.30 and its 200 day moving average price is $58.29. Intra-Cellular Therapies, Inc. has a 12-month low of $42.01 and a 12-month high of $67.05.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.17. Intra-Cellular Therapies had a negative return on equity of 28.63% and a negative net margin of 50.40%. The company had revenue of $110.80 million for the quarter, compared to the consensus estimate of $106.45 million. During the same quarter in the prior year, the business earned ($0.92) EPS. Intra-Cellular Therapies’s revenue was up 99.4% on a year-over-year basis. Analysts expect that Intra-Cellular Therapies, Inc. will post -2.08 earnings per share for the current fiscal year.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.